A phase II trial of MCB 3837 for the treatment of Clostridium difficile infection

Trial Profile

A phase II trial of MCB 3837 for the treatment of Clostridium difficile infection

Planning
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2016

At a glance

  • Drugs MCB 3837 (Primary)
  • Indications Clostridium infections
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 28 Jun 2016 New trial record
    • 22 Jun 2016 According to a Morphochem Inc. media release, the US FDA has accepted IND application for MCB 3837 intended to treat Clostridium difficile infection.
    • 22 Jun 2016 This trial is expected to initiate in the second half of 216, according to a Morphochem Inc. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top